ES8106407A1 - Procedimiento para el tratamiento de superficies hidrofobas - Google Patents

Procedimiento para el tratamiento de superficies hidrofobas

Info

Publication number
ES8106407A1
ES8106407A1 ES494356A ES494356A ES8106407A1 ES 8106407 A1 ES8106407 A1 ES 8106407A1 ES 494356 A ES494356 A ES 494356A ES 494356 A ES494356 A ES 494356A ES 8106407 A1 ES8106407 A1 ES 8106407A1
Authority
ES
Spain
Prior art keywords
proteins
denaturization
utilization
manufacture
aqueous solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES494356A
Other languages
English (en)
Other versions
ES494356A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2917535A external-priority patent/DE2917535C2/de
Priority claimed from DE19792952119 external-priority patent/DE2952119A1/de
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of ES494356A0 publication Critical patent/ES494356A0/es
Publication of ES8106407A1 publication Critical patent/ES8106407A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROCEDIMIENTO DE ELIMINACION DEL EFECTO ABSORBENTE Y DESNATURALIZADOR SOBRE PROTEINAS EN SUPERFICIES HIDROFOBAS. CONSISTE EN RETICULAR LAS SUPERFICIES CON UNA SOLUCION ACUOSA DE UNA SUSTANCIA TENSOACTIVA CON UNA ESTRUCTURA FUNDAMENTAL EN FORMA DE CADENA, CUYOS MIEMBROS CONTIENEN ZONAS DEBILMENTE HIDROFOBAS Y DEBILMENTE HIDROFILAS EN DISPOSICION ALTERNADA. LA SUSTANCIA TEMPOACTIVA EMPLEADA ES UN HOMOPOLIMERO COPOLIMERO O POLIMERO POR BLOQUES DE FORMULA R2Y-XN-R3; R3 SIGNIFICA ALCOHILO CON 1-20 ATOMOS DE CARBONO, CARBOXIALCOHILO CON 2-20 ATOMOS DE CARBONO O ALCOHILFENILO CON 1-10 ATOMOS DE CARBONO EN LA PARTE ALCOHILO; R2 SIGNIFICA ALCOHILO CON 1-20 ATOMOS DE CARBONO, CARBOXIALCOHILO CON 2-20 ATOMOS DE CARBONO O ALCOHILFENILO CON 1-20 ATOMOS DE CARBONO EN LA PARTE ALCOHILA.
ES494356A 1979-04-30 1980-08-19 Procedimiento para el tratamiento de superficies hidrofobas Expired ES8106407A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2917535A DE2917535C2 (de) 1979-04-30 1979-04-30 Gegen Denaturierung beständige Insulinlösungen
DE19792952119 DE2952119A1 (de) 1979-12-22 1979-12-22 Gegen denaturierung bestaendige, waessrige protein-loesungen

Publications (2)

Publication Number Publication Date
ES494356A0 ES494356A0 (es) 1981-07-16
ES8106407A1 true ES8106407A1 (es) 1981-07-16

Family

ID=25778936

Family Applications (1)

Application Number Title Priority Date Filing Date
ES494356A Expired ES8106407A1 (es) 1979-04-30 1980-08-19 Procedimiento para el tratamiento de superficies hidrofobas

Country Status (11)

Country Link
US (1) US4885164A (es)
EP (1) EP0018609B1 (es)
AU (1) AU535040B2 (es)
CA (1) CA1146069A (es)
DE (1) DE3064888D1 (es)
DK (1) DK160459C (es)
EG (1) EG15017A (es)
ES (1) ES8106407A1 (es)
FI (1) FI70671C (es)
GR (1) GR67209B (es)
IL (1) IL59933A (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1011126A1 (ru) * 1981-07-14 1983-04-15 Всесоюзный научно-исследовательский и испытательный институт медицинской техники Средство дл лечени сахарного диабета
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
CA1244347A (en) * 1984-05-29 1988-11-08 Eddie H. Massey Stabilized insulin formulations
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
DE3443877A1 (de) * 1984-06-09 1985-12-12 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung
WO1989007945A1 (en) * 1988-02-26 1989-09-08 Genentech, Inc. Human relaxin formulation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
DE19722950A1 (de) * 1997-05-31 1998-12-03 Huels Chemische Werke Ag Renaturierung von Eiweißstoffen
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP0917879B1 (de) 1997-11-22 2002-07-17 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Stabilisierung von Proteinen
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
EP3385870A1 (en) 2008-06-20 2018-10-10 Novartis AG Immunoglobulins with reduced aggregation
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
JP5670421B2 (ja) 2009-03-31 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング コンポーネント表面のコーティング方法
EP3508239B1 (de) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
SI2554183T1 (en) 2009-11-13 2018-08-31 Sanofi-Aventis Deutschland Gmbh A pharmaceutical composition comprising the GLP-1 agonist and insulin and methionine
RU2573995C2 (ru) 2009-11-13 2016-01-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, содержащая агонист гпп-1 и метионин
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
KR101782306B1 (ko) 2009-11-25 2017-09-27 베링거 인겔하임 인터내셔날 게엠베하 분무기
US20130028920A1 (en) 2010-03-31 2013-01-31 Universite De Geneve Stabilized antibody preparations and uses thereof
EP2552411A2 (en) 2010-03-31 2013-02-06 Université de Genève Stabilized antibody preparations and uses thereof
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
SI2611458T1 (sl) 2010-08-30 2017-01-31 Sanofi-Aventis Deutschland Gmbh Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
PT2750699E (pt) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Acelerómetro pendular
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
KR20150082640A (ko) 2012-11-13 2015-07-15 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
HUE055604T2 (hu) 2014-05-07 2021-12-28 Boehringer Ingelheim Int Porlasztó
ES2954961T3 (es) 2014-05-07 2023-11-27 Boehringer Ingelheim Int Unidad, nebulizador y método
KR102443739B1 (ko) 2014-05-07 2022-09-19 베링거 인겔하임 인터내셔날 게엠베하 분무기 및 컨테이너
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
IL270975B2 (en) 2017-06-01 2024-02-01 Lilly Co Eli Fast-acting insulin preparations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2212695A1 (de) * 1972-03-16 1973-09-20 Hoechst Ag Verfahren zur reinigung von insulin und insulinderivaten
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1554157A (en) * 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1563311A (en) * 1975-09-26 1980-03-26 Yamanouchi Pharma Co Ltd Pharmaceutical composition of insulin for rectal use
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
CA1244347A (en) * 1984-05-29 1988-11-08 Eddie H. Massey Stabilized insulin formulations

Also Published As

Publication number Publication date
DK185180A (da) 1980-10-31
FI70671B (fi) 1986-06-26
AU535040B2 (en) 1984-03-01
DK160459B (da) 1991-03-18
ES494356A0 (es) 1981-07-16
US4885164A (en) 1989-12-05
DE3064888D1 (en) 1983-10-27
GR67209B (es) 1981-06-24
EP0018609B1 (de) 1983-09-21
EP0018609A1 (de) 1980-11-12
AU5787780A (en) 1980-11-06
FI70671C (fi) 1986-10-06
DK160459C (da) 1991-08-26
IL59933A (en) 1984-06-29
CA1146069A (en) 1983-05-10
IL59933A0 (en) 1980-06-30
EG15017A (en) 1985-12-31
FI801361A (fi) 1980-10-31

Similar Documents

Publication Publication Date Title
ES8106407A1 (es) Procedimiento para el tratamiento de superficies hidrofobas
ES2077530A1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
HUT44793A (en) Process for production of 19-nor or 19-nor-d-homo stereoids substituated in position 11-beta by alkinylphenil group and medical preparatives containing them as active substance
ATE2113T1 (de) Verfahren zur herstellung von festen arzneimitteln mit troepfchenfoermig aufgebrachten wirkstoffen.
DE3479632D1 (en) Fibronolytically active hybrid protein, process for its preparation and pharmaceutical composition
DE3572179D1 (en) Blood coagulation inhibiting proteins, process for preparing them and their use
DE3461886D1 (en) Process for preparing a whey product
EP0322687A3 (en) Method for the manufacture of a product having at least one substance embedded in a carrier
ES478047A1 (es) Procedimiento para la obtencion de acidos 4-piridon-3-car- boxilicos.
EP0216742A3 (en) Growth factors
IT1151741B (it) Soluzione per dialisi contenente glucosio, aminoacidi e insulina
PT87658A (pt) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet loesung enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
ES8503643A1 (es) Un procedimiento para la preparacion de compuestos de bis (carboxamida)
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
EP0188262A3 (en) Process for the isolation of chicken egg white cystatine, antiviral agents containing it and its use as viral protease inhibitor
ATE26213T1 (de) Aeusserlich anzuwendende arzneimittelzubereitung enthaltend adenosin zur behandlung von herpes.
FI95778C (fi) Menetelmä taudinaiheuttajien inaktivoimiseksi biologisessa tai farmaseuttisessa aineessa
JPS57193494A (en) Method of purifying or concentrating biologically active protein and drug therefor
AU2740384A (en) Inactivation of viruses in virus containing protein samples
CH609863A5 (en) Cosmetic treatment process and products enabling it to be carried out
ES465180A1 (es) Procedimiento para la preparacion de preparados de inmuno- globulinas
EP0372522A3 (en) Dieting agents comprising alpha-amylase inhibiting substances from wheat
HUT36783A (en) Process for preparing 1,7-diphenyl-3-methyl-aza-7-cyano-8-methyl-nonane
DE3872628T2 (de) Makrozyklische liganden, an siliziumoxyd oder kieselgel gebunden, und deren verwendung zum selektiven und quantitativen entfernen und konzentrieren von in geringer konzentration gegenwaertigen ionen aus anderen ionen enthaltenden mischungen.
ES8801506A1 (es) Procedimiento para preparar disulfuros heterociclicos